ABT-263 (Navitoclax)

ABT-263 (Navitoclax) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with Ki ~ 0.5 nM, 1 nM and 1 nM in cell-free assays. ABT-263 blocks the Bcl-2/Bcl-xL interactions, thereby promoting apoptosis.

Additional Information

Product Name: ABT-263 (Navitoclax)
Also Known As: 4-​[4-​[[2-​(4-​chlorophenyl)​-​5,​5-​dimethyl-​1-​cyclohexen-​1-​yl]​methyl]​-​1-​piperazinyl]​-​N-​[[4-​[[(1R)​-​3-​(4-​morpholinyl)​-​1-​[(phenylthio)​methyl]​propyl]​amino]​-​3-​[(trifluoromethyl)​sulfonyl]​phenyl]​sulfonyl]​-benzamide
Catalog No.: F7141
Size: 25 mg
CAS: N/A
Formula: C47H55ClF3O6S3
Molecular Weight: 974.61 g/mol
Form: Lyophilized powder
Quality Assurance: >98% by HPLC and NMR
Source: Synthetic
Storage: Eligible for room temperature shipping. Store at -20°C upon receiving; protect from air and ligh
PDF Data Sheet: Download PDF datasheetMSDS
Image(s): N/A
Shipping Method: Room temperature shipping
References: Tse C, et al. (2008) Cancer Res. 68(9), 3421-3428.

Details

ABT-263 (Navitoclax) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with Ki ~ 0.5 nM, 1 nM and 1 nM in cell-free assays. ABT-263 blocks the Bcl-2/Bcl-xL interactions, thereby promoting apoptosis.

Solubility:
> 20 mg/ml in DMSO

Working Condition:
1 μM in cell culture assay